RU94026296A - Эфиры трискарбаминовой кислоты: ингибиторы абсорбции холестерина - Google Patents

Эфиры трискарбаминовой кислоты: ингибиторы абсорбции холестерина

Info

Publication number
RU94026296A
RU94026296A RU94026296/04A RU94026296A RU94026296A RU 94026296 A RU94026296 A RU 94026296A RU 94026296/04 A RU94026296/04 A RU 94026296/04A RU 94026296 A RU94026296 A RU 94026296A RU 94026296 A RU94026296 A RU 94026296A
Authority
RU
Russia
Prior art keywords
cholesterol
cholesterol absorption
tris
inhibitors
acid esters
Prior art date
Application number
RU94026296/04A
Other languages
English (en)
Other versions
RU2130928C1 (ru
Inventor
Джозеф Коммонс Томас
Us]
Питер Страйк Дональд
Мари ЛяКлер Криста
Original Assignee
Американ Хоум Продактс Корпорейшн (Us)
Американ Хоум Продактс Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Американ Хоум Продактс Корпорейшн (Us), Американ Хоум Продактс Корпорейшн filed Critical Американ Хоум Продактс Корпорейшн (Us)
Publication of RU94026296A publication Critical patent/RU94026296A/ru
Application granted granted Critical
Publication of RU2130928C1 publication Critical patent/RU2130928C1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

Ингибирование ферментов гидролазы эфиров холестерина (ГЭХ) и/или ацил-софермента А: ацилтрансферазу холестерина (АТАХ) приводит к ингибированию этерификации холестерина и посредством этого к ингибированию абсорбции холестерина. В результате может быть понижено содержание сывороточного холестерина. Соединение, имеющее формулузаместитель Z представляет собой, а А представляет собой связующую группу ингибирует ферменты ГЭХ и/или АТАХ (in vitro) и ингибирует абсорбцию холестерина.

Claims (1)

  1. Ингибирование ферментов гидролазы эфиров холестерина (ГЭХ) и/или ацил-софермента А: ацилтрансферазу холестерина (АТАХ) приводит к ингибированию этерификации холестерина и посредством этого к ингибированию абсорбции холестерина. В результате может быть понижено содержание сывороточного холестерина. Соединение, имеющее формулу
    Figure 00000001

    заместитель Z представляет собой
    Figure 00000002
    , а А представляет собой связующую группу ингибирует ферменты ГЭХ и/или АТАХ (in vitro) и ингибирует абсорбцию холестерина.
RU94026296A 1993-07-21 1994-07-15 Эфиры трискарбаминовой кислоты, способ уменьшения абсорбции холестерина и фармкомпозиция для понижения абсорбции холестерина RU2130928C1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/095,140 US5952354A (en) 1993-07-21 1993-07-21 Tris carbamic acid esters: inhibitors of cholesterol absorption
US08/095,140 1993-07-21

Publications (2)

Publication Number Publication Date
RU94026296A true RU94026296A (ru) 1997-05-27
RU2130928C1 RU2130928C1 (ru) 1999-05-27

Family

ID=22250071

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94026296A RU2130928C1 (ru) 1993-07-21 1994-07-15 Эфиры трискарбаминовой кислоты, способ уменьшения абсорбции холестерина и фармкомпозиция для понижения абсорбции холестерина

Country Status (16)

Country Link
US (1) US5952354A (ru)
EP (1) EP0635501A1 (ru)
JP (1) JPH0789934A (ru)
KR (1) KR950003269A (ru)
AU (1) AU692157B2 (ru)
BR (1) BR9402852A (ru)
CA (1) CA2128116A1 (ru)
FI (1) FI943441A (ru)
HU (1) HU216790B (ru)
IL (1) IL110302A (ru)
MX (1) MX9405430A (ru)
NZ (1) NZ264032A (ru)
RU (1) RU2130928C1 (ru)
SG (1) SG47596A1 (ru)
TW (1) TW369527B (ru)
ZA (1) ZA945214B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5527804A (en) * 1994-06-13 1996-06-18 American Home Products Corporation 4-carbamoyloxy-piperidine-1-carboxylic acid esters: inhibitors or cholesterol absorption
HUP9900617A3 (en) 1995-10-05 2001-12-28 Kyoto Pharma Ind Novel indole-, indoline- or tetrahydrokinoline derivatives as acat and lipid peroxidation inhibitors, use thereof, pharmaceutical compositions containing these compounds
US5952506A (en) * 1997-04-24 1999-09-14 American Home Products Corporation Process for the synthesis of 4- 6- (hexylcarbamoyloxy) hexylcarbamoyloxy!-piperidine-1-carboxylic acid 4-phenoxyphenyl ester
WO1998047870A1 (en) * 1997-04-24 1998-10-29 American Home Products Corporation Process for the synthesis of 4-[6-(hexylcarbamoyloxy) hexylcarbamoyloxy]-piperidine-1- carboxylic acid 4-phenoxyphenyl ester
US20100324075A1 (en) * 2007-12-21 2010-12-23 University Of Cincinnati Therapeutic use of carboxyl ester lipase inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2800105A1 (de) * 1977-01-11 1978-07-13 Ciba Geigy Ag Verwendung von diphenylaethern als algizide
JPS5671058A (en) * 1979-11-12 1981-06-13 Mitsui Toatsu Chem Inc Phenoxyphenylcarbamic ester derivative
DE3702876A1 (de) * 1987-01-31 1988-08-11 Merck Patent Gmbh Optisch aktive verbindungen
FR2612186B1 (fr) * 1987-03-09 1989-07-21 Poudres & Explosifs Ste Nale Carbonyl 2,2' bis (alkyl-4 oxadiazolidines-1,2,4-diones-3,5), leur procede de preparation et leur utilisation comme intermediaires de synthese dans la preparation de carbamates
US5142094A (en) * 1989-11-06 1992-08-25 Warner-Lambert Company Aryl substituted carbamate derivatives which are acat inhibitors
IL95994A0 (en) * 1989-11-15 1991-07-18 American Home Prod Carbamate esters and pharmaceutical compositions containing them
US5112859A (en) * 1990-09-14 1992-05-12 American Home Products Corporation Biphenyl amide cholesterol ester hydrolase inhibitors
US5169844A (en) * 1991-12-20 1992-12-08 American Home Products Corporation 4-substituted piperidinecarboxylic acid esters: inhibition of cholesterol absorption

Also Published As

Publication number Publication date
KR950003269A (ko) 1995-02-16
HU216790B (hu) 1999-08-30
SG47596A1 (en) 1998-04-17
RU2130928C1 (ru) 1999-05-27
AU6752094A (en) 1995-02-02
US5952354A (en) 1999-09-14
ZA945214B (en) 1996-01-15
IL110302A (en) 1998-06-15
TW369527B (en) 1999-09-11
IL110302A0 (en) 1994-10-21
JPH0789934A (ja) 1995-04-04
EP0635501A1 (en) 1995-01-25
AU692157B2 (en) 1998-06-04
FI943441A (fi) 1995-01-22
FI943441A0 (fi) 1994-07-20
NZ264032A (en) 1995-12-21
HU9402108D0 (en) 1994-09-28
CA2128116A1 (en) 1995-01-22
HUT70942A (en) 1995-11-28
MX9405430A (es) 1995-01-31
BR9402852A (pt) 1995-04-04

Similar Documents

Publication Publication Date Title
Antonov et al. n-Alkylboronic acids as bifunctional reversible inhibitors of a-chymotrypsin
RU2000106434A (ru) N-алканоилфенилаланиновые производные
RU94045141A (ru) Гетероциклические производные карбоновой кислоты и их соли и фармацевтическая композиция с антифибротической или тормозящей пролилгидроксилазу или биосинтез коллагена активностью
EP0352864A3 (en) Compounds active as inhibitors of the cholesterol biosynthesis
IL86464A (en) 4-phosphinyl-3- hydroxybutanoic acid derivatives useful as cholesterol biosynthesis inhibitors and pharmaceutical compositions containing the same
RU94046149A (ru) Новые n-арил и n-гетероарил производные мочевины как ингибиторы ацил кофермента а:холестерин ацил трансферазы (асат) фармацевтическая композиция, способ ингибирования (асат)
ID16141A (id) Proses untuk produksi asam akrilat
FI956341A (fi) Metyylifosfonihappoesteri, menetelmä sen valmistamiseksi ja sen käyttö
CA2130116A1 (en) Aminoacetylmercaptoacetylamide Derivatives Useful as Inhibitors of Enkephalinase and Ace
YU48670B (sh) POSTUPAK ZA DOBIJANJE (2R,3R)-CIS-Гџ-FENILGLICIDNE KISELINE
DE69712890T2 (de) Herstellung von sorbitan-fettsäureestern als oberflächenaktive stoffe
DE69302098T2 (de) Zusammensetzungen von hexitan-fettsäureestern
RU94026296A (ru) Эфиры трискарбаминовой кислоты: ингибиторы абсорбции холестерина
FI891331A (fi) Ytaktiva foereningar och deras framstaellningsfoerfarande cer-2.
DE3768138D1 (de) Substituierte pyrimidinamide von oelsaeure oder linolsaeure als inhibitoren von acyl-coa cholesterin-acyltransferase.
EP0489839A4 (en) Novel hydrolytic enzyme inhibitors and substrates and assays, methods and kits embodying same
GB2324528B (en) Cytostatic hydroxamic acid derivatives
DE59810578D1 (de) Mischungen von langkettigen Phosphorsäurealkylestern
AU7735896A (en) Aryl acrylic acid derivatives useful as protein tyrosine phosphatase inhibitors
ES2147196T3 (es) Procedimiento para la hidrolisis estereoespecifica de derivados de piperidindiona.
DE59808546D1 (de) Verwendung von fettsäureniedrigalkylestern in abbeizmitteln
AU635087B2 (en) Cholesterol ester hydrolase inhibitors
DE59404990D1 (de) Fettsäureester von Methylglucosid-Derivaten
Mounter et al. Specificity and properties of wheat-germ esterase
IT1175395B (it) Composto carbonato, suo metodo di produzione e suoi impieghi come reagente per formare un estere attivo di amino acidi